Perspectives

Lumanity convened medical and pharmacy directors from six large national and regional US payers with at least 25% Medicare business to share their perspectives on both the Maximum Fair Price (MFP) drug price negotiation and Part D redesign components of the IRA. Read the six key insights from our panel.

One of the biggest challenges in the biotech and pharmaceutical industry today is achieving market expectations for a new approved therapy. Clinical development teams are laser-focused on regulatory approval. However, it is possible to gain approval and still experience a less than optimal commercialization due to changes in the therapeutic landscape, a lack of data for payer access, or a patient-averse regimen. Early incorporation of external advice into the development program decision process can reduce this risk and potentially improve commercialization.

Lumanity's Clinical and Regulatory team developed a tailored and comprehensive literature monitoring strategy to keep all stakeholders informed of the latest and relevant science.